雅本化学 reported revenue of ¥0.60B for the period ended 2026-06-30, -9.8% year on year. Net income was ¥-0.16B, a -27.0% net margin on a 3.2% gross margin. The largest revenue line is 农药中间体 at 68% of the total. Free cash flow for the period was ¥0.03B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.60B | -9.8% |
| Gross profit | ¥0.02B | — |
| Operating income | ¥-0.19B | — |
| Net income | ¥-0.16B | — |
| Gross margin | 3.2% | Net margin -27.0% |
| Revenue Q/Q | -3.4% | — |
| Segment | Revenue | Share |
|---|---|---|
| 农药中间体 | ¥0.41B | 68.4% |
| 医药中间体 | ¥0.14B | 23.6% |
| 其他(补充) | ¥0.02B | 3.5% |
| 环保产业 | ¥0.02B | 3.1% |
| 特种化学品 | ¥0.01B | 1.5% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.58B | 96.8% |
| R&D | ¥0.04B | 7.3% |
| SG&A | ¥0.08B | 13.9% |
| Tax & other | ¥-0.03B | -4.5% |
| Item | Amount |
|---|---|
| Total assets | ¥3.88B |
| Total liabilities | ¥2.09B |
| Shareholders' equity | ¥1.79B |
| Equity / assets | 46.1% |
| Operating cash flow | ¥0.08B |
| Capital expenditure | ¥0.05B |
| Free cash flow | ¥0.03B |
| Cash conversion (OCF / net income) | -124% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
隆华科技 ・ 佳创视讯 ・ 通光线缆 ・ 兴源环境 ・ 尔康制药 ・ 佳沃食品 ・ 联建光电 ・ 中威电子 ・ 华宇软件 ・ 开能健康 ・ 梅安森 ・ 三丰智能
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies